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Breast cancer is the second most common cause of cancer related death in women in the
United States with one in eight women expected to develop the disease in their lifetime.
Unfortunately, breast cancer is the leading cause of cancer related death among African
American women. African American women are four times more likely to die from breast
cancer that Caucasian women. Mammography screenings are the most effective method of
reducing breast cancer mortality in African American women. This study aimed to determine
if the changes made to the mammography screening recommendations put forth by the U.S.
Preventive Services Task Force in November 2009 and later re-enforced in January 2016
create an increased burden of breast cancer diagnoses among African American women. The
study does so by addressing whether changing the time interval between mammography
screenings affects the likelihood of African American women being diagnosed with breast
cancer and if African American women typically present with knowledge of their family
history of breast cancer. The U.S. Preventive Services Task Force used the fact that the
majority of women develop breast cancer in their 60s and the burden caused by false

positives to support their decision to change the screening recommendations, however,
literature describes a higher incidence of aggressive breast cancers and earlier onset of
disease in African American women. Data from the Breast Cancer Surveillance Consortium
was used to run multivariate regression analyses of breast cancer diagnosis within a year of
the previous mammography screening and the presence of knowledge of family history at the
time of mammography screening. A significant association was not found between race and
the likelihood of being diagnosed with either invasive or non-invasive breast cancer.
However, African American women had a higher proportion of women without knowledge
of their family history of breast cancer. This research fills an important gap in understanding
how the recommendation changes can influence the mortality and morbidity of African
American women that develop breast cancer. Its implications include potential policy
changes on the mammography screening recommendations given specifically for African
American women.
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INTRODUCTION
This dissertation seeks to determine if the changes made to the mammography screening
recommendations in November 2009 and later re-enforced in January 2016 create an increased
burden of breast cancer diagnoses among African American women.1 While the argument has
been made for the change in screening recommendations due to the majority of women
developing breast cancer in their 60s and the burden caused by false positives, recent literature
describes a higher incidence of aggressive breast cancers and earlier onset of disease in African
American women.2
Much of the literature surrounding African American women and breast cancer has
focused on the causes of increased mortality and morbidity of breast cancer among African
American women compared to their Caucasian counterparts. Historically, researchers focused on
these areas because African American women had higher rates of mortality and morbidity
though Caucasian women were more likely to be diagnosed with breast cancer.2-7 The literature
has documented that African American women are more likely to be diagnosed with a late-stage
breast cancer due to a myriad of reasons 2,8-27, but the impact of increasing the time interval
between mammography screenings from one year to two years has not been reported. Therefore,
this study will determine if the changes to the mammography screening recommendations has
the potential to cause more African American women to be diagnosed with a breast cancer.
The study used mammography screening history and date of diagnosis as determinants of
the threat of greater incidence. This research fills an important gap in understanding how the
recommendation changes can influence the mortality and morbidity of African American women
that develop breast cancer. Its implications include potential policy changes on the
mammography screening recommendations given specifically for African American women.
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BACKGROUND
Literature Review
Breast cancer is the second most common cause of cancer related death in women in the
United States with one in eight women expected to develop the disease in their lifetime.5 Breast
cancer can be detected through physical examination of the breast28 but is most commonly
detected through mammography screenings. Other screening methodologies exist, such as
ultrasound, digital breast tomosynthesis, and magnetic resonance imaging; however,
mammography screenings are directly linked to reducing breast cancer mortality by discovering
the cancer before signs and symptoms present and are the most effective method of reducing
late-stage diagnoses in African American women.10,29,30 For women aged 40-60 years,
mammography screenings have been shown to reduce mortality from breast cancer by 1532%.9,31,32 Mammography screenings have also been found to be the most cost effective method
of diagnosing breast cancer.33 Staging is a method of categorizing the progression of the disease
by describing the size, location, and spread of the breast cancer. There are five stages of breast
cancer, zero through four. Stage zero is noninvasive ductal carcinoma in situ (DCIS). Stages one
through four are invasive breast cancers and they are categorized by early/localized, locally
advanced, and metastatic states.28


Early or Localized: Stage I, Stage II, and Stage IIIA



Locally Advanced: Stage IIIB and Stage IIIC



Metastatic Breast Cancer: Stage IV

Stage is determined by the size of the tumor and whether or not the cancer has spread to
neighboring tissues, lymph nodes, and distal parts of the body. Discovering the presence of the
disease while it is categorized as Stage I or II yields a 100% and 93% 5-year survival rate,
2

respectively. Stage III has a 72% 5-year survival rate and Stage IV has only a 22% 5-year
survival rate.34 The drastic decline in survival likelihood has caused stage III and IV breast
cancers to be termed late-stage breast cancers. The earlier a breast cancer is detected, the more
likely a woman is to survive.
Incidence
In the United States, 12.8% of women can expect to develop breast cancer at some point in their
lives.4 There will be an estimated 268,600 new cases of breast cancer and 41,760 deaths in
2019.35 Among African American women, there is an expected 33,840 cases and 6,540 deaths in
2019.5 This study focuses on the difference between African American and Caucasian women
because non-Hispanic black and non-Hispanic white women both have higher incidence and
death rates for breast cancer than other races/ethnicities.4 The incidence of breast cancer is
increasing for both non-Hispanic whites and non-Hispanic blacks.5 Speaking to the significance
of late-stage diagnoses, Healthy People 2020 has separate goals for reducing breast cancer
mortality and reducing the rate of late-stage cancer diagnoses.14 African American women
experience elevated death rates and poorer survival rates for breast cancer nationally.4,5
Treatments and Quality of Life
There are six types of standard treatments for breast cancer: surgery, radiation therapy,
chemotherapy, hormone therapy, target therapy, and immunotherapy.28 Breast-conserving
surgery removes the cancerous tumor and some of the tissue surrounding the tumor but leaves
the breast. These procedures can be referred to as a lumpectomy, partial mastectomy, segmental
mastectomy, or quadrantectomy. The surgical removal of the entire breast is a simple or total
mastectomy. When conducting a mastectomy, neighboring lymph nodes may also be removed. A
modified radical mastectomy removes the entire breast as well as the lymph nodes under the arm,
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the lining over the chest muscles, and a portion of the chest wall muscles. Radiation therapy uses
high energy x-rays to kill the cancerous cells or prevent further growth of the tumor.
Chemotherapy uses oral or intravenous drugs to kill the cancerous cells or prevent further growth
of the tumor. Hormone therapy removes the hormones that aid in the tumor’s growth through
drugs, surgery, or radiation. Targeted therapy uses drugs, antibodies, and other substances to kill
specific cancerous cells while not harming normal tissue. Lastly, immunotherapy uses the body’s
immune system to kill the cancer by using substances to boost or restore the body’s defenses. For
the purposes of this study, targeted therapies and chemotherapy will be reported together.36
Breast cancer treatments are tailored to the stage and type. An early or localized breast
cancer is treated with surgery. The surgical treatment can range from either breast conserving to
modified radical mastectomy. Postoperative radiation can also be given to ensure the cancer does
not return. In the case of a locally advanced breast cancer, the prescribed treatment is usually
surgery, chemotherapy before and/or after surgery, radiation therapy, and hormone therapy.
Treatment of metastatic breast cancer includes all six treatment options with the surgical
treatment being a total mastectomy and surgical removal of the cancerous tumors for other areas
of the body. The complexity of treatment increases considerably for late-stage breast cancers.
There are also types of breast cancers that are defined by the biomarkers present on the
cancerous cells. Biomarker testing identifies the presence of estrogen receptors, progesterone
receptors, and human epidermal growth factor type 2 receptor (HER2). If the breast cancer cells
have larger than normal amounts of HER2 receptors on their surface, the cancer cells are called
HER2 positive (HER2+). If the breast cancer cells have a normal amount of HER2 on their
surface, the cancer cells are called HER2 negative (HER2-). If the breast cancer cells do not have
estrogen receptors, progesterone receptors, or an abnormally large amount of HER2 receptors,
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the cancer cells are called triple negative. If the breast cancer cells do have estrogen receptors,
progesterone receptors, and an abnormally large amount of HER2 receptors, the cancer cells are
called triple positive. Triple negative breast cancer is treated with conventional chemotherapy,
but adjuvant chemotherapy is recommended for tumors ≥6 mm and radiation therapy for tumors
>5 cm.37 Knowing the type of breast cancer helps inform how best to treat the cancer. HER2+
breast cancer is more likely to grow and divide faster than HER2- breast cancer.
Cancer treatments are designed to destroy cancerous cells and cannot always discriminate
good cells from unwanted cells. The more advanced the cancer, the more invasive the treatment.
The increase in each of these treatments causes more lasting damage to the body. Some of the
side effects to cancer treatment are pain, nausea, vomiting, anemia, fatigue, physical limitations,
infection, lymphedema, and depression.38 Of these side effects breast cancer survivors report a
diminished quality of life from lymphedema, sexual problems, restricted physical abilities, and
depression.39,40 These quality of life issues can remain long after the actual cancer treatments
have been completed. Therefore, the costs of a late-stage cancer diagnosis extends beyond the
physical treatment of the cancer.
Late effects appear months to years after breast cancer treatment. Recipients of radiation
can experience lung inflammation, especially if chemotherapy was given at the same time as the
radiation, arm lymphedema, and the development of breast cancer in the remaining breast for
women under the age of 45. Chemotherapy can cause blood clots, premature menopause, heart
failure, or the development of another cancer. Targeted therapy can also lead to heart failure.28
Incidence and Mortality in African American Women
Breast cancer is the most commonly diagnosed cancer in African American women and
accounts for a third of all the cancer diagnoses.5 Historically, non-Hispanic white women have
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had a higher incidence of breast cancer than non-Hispanic black women. In recent years, the
incidence rates of non-Hispanic white women and non-Hispanic black women have converged.5
From 2005-2014 breast cancer incidence rates increased among non-Hispanic black women but
remained stable for non-Hispanic white women.4 Compared to non-Hispanic white women, nonHispanic black women have a higher incidence of breast cancer before age 40 but lower
incidence rates for the 65-84 age range.4 Non-Hispanic black women have a higher incidence of
breast cancer in their 40s than non-Hispanic white women. They also have a higher proportion of
estrogen receptor negative breast cancer especially under the age of 50.6 Previous studies found
that the incidence rate of metastatic breast cancer among young non-Hispanic white and nonHispanic black women, or early onset de novo metastatic breast cancer, were increasing.41,42
However, DeSantis et al., found that when accounting for the sharp decrease in unstaged breast
cancers the incidence rate among non-Hispanic white women levels off but continues to increase
and remain statistically significant for non-Hispanic black women.5
Non-Hispanic black women are more likely to die from breast cancer at every age. The
five-year breast cancer survival rate is lowest for non-Hispanic black women.4 The highest
mortality rates are seen among the age group with the smallest mortality disparity between nonHispanic white women and non-Hispanic black women, age 65 and over.6 Although the
mortality rates are lower among women under 40 and women 40-49, the highest mortality
disparity between non-Hispanic white and non-Hispanic black women was found in these two
age groups.6 Overall, 81% of breast cancers were diagnosed in women age 50 years or older with
89% of the deaths occurring in this age group. The median age of breast cancer diagnosis
(White: 63 years, Black: 59 years) and death (White: 70 years, Black: 62 years) is lower in
African American women.4,5 Breast cancer survival rates for non-Hispanic black women are
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81% for regional cancers and 26% for distant cancers compared to 89% and 37% for nonHispanic white women.4
Disparity Causes
Personal Factors
Non-Hispanic black/African American women consistently have the highest prevalence
of late-stage breast cancer diagnoses.8,13,43 Mobley et al. named being categorized as NonHispanic black or African American as the number one predictor for being diagnosed with latestage breast cancer.16 The high mortality rate is due, in some part, to the point in disease
progression at which African American women are diagnosed with breast cancer. African
American women are more likely than Caucasian women to be diagnosed with a late-stage breast
cancer, thereby decreasing their likelihood of survival.16
Behaviors causally linked to a late-stage cancer diagnosis are the same behaviors linked
to developing breast cancer in general. These are smoking, alcohol consumption, a lack of
breastfeeding, use of hormone therapy, having a body mass index over 25, and a lack of physical
activity,9 all of which are prevalent in the African American community.5
An additional risk factor for being diagnosed with late-stage breast cancer is having a low
socioeconomic status. With the presence of health insurance being a major contributing factor to
the utilization of preventive health services among African American women, the lack of health
insurance becomes a barrier for the women of this population.18 The perceived prohibitive costs
prevents some employers from providing health insurance to all of their employees.44 The
presence of employer-sponsored health insurance, specifically, directly affects the use of health
care services even in people with known high susceptibility to developing cancer.45
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Under insured or uninsured women under the age of 65 are most at risk for being
diagnosed with late-stage breast cancer.16 Some women with low socioeconomic statuses have to
choose between going to a doctor’s appointment or receiving a full day’s pay.10 Women living
near and below the poverty line are more likely to be diagnosed with later-stage breast cancer
and African American women are twice as likely to live below the federal poverty limit as white
women.5
Mammography screenings are directly linked to reducing breast cancer mortality by
discovering the cancer before signs and symptoms present.29 For women aged 40 – 60 years,
mammography screenings have consistently shown to reduce mortality from breast cancer by 1532%.9 The research has found a plethora of reasons low-income minority women fail to receive
mammography screenings in a timely enough fashion to prevent late-stage breast cancer
diagnosis.10 Reasons can effectively be grouped by construct to get a sense of thematic patterns
driving behavior. Behavior capability is an issue with a majority of women reporting that merely
knowing where to go to receive a mammography screening, scheduling screenings, and not
having adequate information regarding the screening were issues preventing them from
completing mammography screenings.46 Likewise, self-efficacy is an obstacle. Women reported
the struggle of taking time off from work, finding adequate transportation, and needing to care
for children and/or elders. For women with knowledge of the mammography screening process,
there were preventive outcome expectations such as women who expressed fear of having the
screening result be a positive diagnosis for breast cancer.46 Women diagnosed with breast cancer
at any stage report a fear of dying.47 A late-stage breast cancer diagnosis would only exacerbate
this fear as a late-stage diagnosis decreases a woman’s chance of survival compared to an early
stage cancer. Even still, women reported perceived barriers such as the cost of screening and the
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possible pain and discomfort experienced during mammography. Social norms generated in a
segregated community were also found to be a hindrance to receiving a mammography screening
particularly when that norm is to not conduct health promoting behaviors.13,48 All of these factors
are compounded by the ongoing feelings of distrust in health care providers in the African
American community as a whole.49-51 The woman’s utilization of health care resources also
depends on the social norms to which the woman subscribes.13,48
Research has found that spatial access to primary health care facilities was more
impactful on late-stage breast cancer diagnoses than was access to mammography screenings in
minority and low-economic status areas.18,52 Access to preventive health services within the
community becomes particularly salient when you consider the additional barrier of access to
transportation. Low socioeconomic African American women are less likely to have personal
vehicles.17 With primary care physicians (PCP) being the first line of defense for preventive
services, it stands to reason that they would also be a key player in reducing the likelihood of
receiving a late-stage breast cancer diagnosis.19 Societal attitudes that led to a decline in the
number of PCPs and a decline in mammography screening rates coupled with the increased
demand in the use of primary care preventive procedures and services create a unique
circumstance where more vulnerable populations could be left without access to mammography
screenings.53,54
Environmental Factors
Interpersonal environmental factors impacting African American women’s likelihood of
receiving a mammography screening include fear of losing a partner, lack of support from family
and friends, and access to transportation.10,55 The presence of positive social support from
intimate partners, family, and friends contributes to the improvement of the quality of life. In
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lower socioeconomic communities, reduced personal vehicle ownership potentially makes travel
dependent on social relationship.17
Access to care is the most debilitating environmental factor with regards to women
receiving mammography screenings.10,13,16 The lack of spatially accessible primary care
clinicians is directly related to late-stage cancer diagnosis. African American women with a
lower socioeconomic status without geographical access to preventive services are at an
increased risk of being diagnosed with late-stage breast cancer. 18 Breast cancer diagnoses and
outcomes are improved by utilization of physicians that were not primary care providers as well
suggesting a health promoting benefit from having access to see any desired physician.19
Being under or uninsured greatly influences the likelihood of a woman pursuing
preventive and diagnostic services.16,19 Many women do not have the option to get a
mammogram without having at least being seen by a PCP.16 The use of mammography
exclusively because of affordability compared to other tests leaves women who require more
sensitive testing measures susceptible to a late-stage diagnosis.16 Regular utilization of
preventive health care services, such as going to see a PCP, has been found to reduce the chance
of late-stage breast cancer.10,29 Research has shown that women with at least 10 visits to a PCP
enjoyed a 50% decreased likelihood of being diagnosed with a late-stage breast cancer, thus
reducing their risk of breast cancer mortality by 41%.19 Without these visits, patients are unable
to be alerted to the signs and symptoms of breast cancer, how to recognize them, and
recommendations for formal screenings. Failure to make the recommended annual preventive
care visits can result in not only the PCP not catching developing symptoms, but the patient
missing patient education delivered during these visits. Women with increased primary care
visits also have a 27% decreased overall mortality rate.19
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Biological Factors
The type of breast cancer with which a woman is diagnosed can impact her likelihood of
being diagnosed with a late-stage breast cancer and her chance of survival. African American
women have a higher incidence of triple negative breast cancer. Triple negative breast cancer is
an aggressive breast cancer and is associated with a worse prognosis.56-59
African American women have been found not to have knowledge of familial cancer
history.24 First- and second-degree relatives with breast cancer spell increased risk of developing
breast cancer; however, African American women with an elevated risk are unable to alert health
care providers of their need for early screenings. The lack of knowledge of family medical
history among African American women is of particular concern for screening recommendations
that delay the start of initial screenings for average risk women.
Current Recommendations
The U.S. Preventive Services Task Force (USPSTF) published their recommendations
and were met with much debate.60 The USPSTF provided an update to their mammography
screening recommendations for average risk women in November 2009. In January 2016, the
USPSTF provided further justification of their recommendations citing that women 60-69 are the
age group of women most likely to avoid breast cancer mortality through mammography
screening and mammography screening at ages 40-49 only avoids a small number of deaths due
to breast cancer, but poses a greater number of harms. They define average risk as a woman
lacking a personal history of breast cancer, a genetic mutation known to increase breast cancer
risk, and/or a history of exposure to chest radiation in childhood. When these conditions are met,
the USPSTF recommends receiving a mammography screening biennially for women 50-74
years. Regardless of the thorough explanation the USPSTF gave for their stance, the published
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recommendations from prominent professional bodies are still quite mixed. Organizations have
sided with U.S. Preventive Services Task Force, others have chosen to continue to recommend
women begin screening at 40, and one organization has developed a completely different
recommendation.
The USPSTF notes that the initiation of regular, biennial mammography screenings
before the age of 50 is an individual decision that should bring into account the benefits and
harms of mammography screenings. The task force conceded the inability to assess the benefits
and harms of mammography screenings in women 75 years of age and older.1 The American
Academy of Family Physicians state that their recommendations mirror those of the U.S.
Preventive Services Task Force.61 Likewise, the American College of Physicians (ACP) suggests
clinicians discuss the potential benefits and harms and a woman's preferences for mammography
screening in average-risk women age 40 to 49. They also make special note that the potential
harms outweigh the benefits in most women age 40 to 49. They recommend biennial
mammography screenings for women age 50 to 74 and the discontinuation of screening in
women age 75 or older and women with a life expectancy of 10 years or less.62
The American Medical Association (AMA), National Comprehensive Cancer Network
(NCCN), and American College of Obstetrics and Gynecology (ACOG) all recommend women
begin screening at age 40. It is also important to note the language the organizations use when
presenting their recommendations because the language shows the value placed on other
organizations recommendations. Some organizations, such as the American Cancer Society
(ACS) and the ACP, state that they use other organization’s recommendations in their
evaluations for their own mammography screening guidelines.62,63 Other organizations state that
their recommendations mirror that of other professional organizations. The AMA state that their
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policy agrees with the guidelines of the following organizations: ACOG; the American College
of Radiology; ACS; the National Cancer Institute; and the NCCN. Their published guidelines are
to initiate annual mammography screenings starting at age 40 for average risk women.64 The
NCCN recommends women aged 40 and older receive mammography screenings but concedes
that the screening interval for women age 40 to 49 is still controversial. In light of that
declaration, they state that the NCCN’s panel has elected to follow the American Cancer
Society’s guidelines of annual mammography screenings.65 The ACOG recommends average
risk women be offered mammography screenings starting at age 40. In the event screening has
not been initiated in their 40s, women should begin mammography screenings by age 50.
Average risk women should have mammography screenings every one or two years based on an
informed, shared decision-making process that includes a discussion of the benefits and harms of
annual or biennial screening and incorporates patient values and preferences. Screening beyond
age 75 should be based on a shared decision-making process between patient and provider
informed by the woman's health status and longevity.66
Lastly, there is the hybrid recommendation of the ACS. With average risk being defined
similarly to that of the USPSTF, the ACS recommends average risk women undergo annual
mammography screenings beginning at the age of 45 and continuing until age 54. Women age 55
and older should begin screening biennially or have the opportunity to continue screening
annually. Women age 40 through 44 should have the opportunity to begin annual screening.
Women should continue mammography screenings as long as they are in good health and they
have a life expectancy of at least 10 years.67,68
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Cause of Recommendation Change
The USPSTF assessed the benefits and harms of mammography screenings. They found
the sensitivity of mammography screening is 77-95% and the specificity is 94-97%.1 False
positives are common and lead to the need for additional imaging tests and invasive procedures
like biopsies. False positives are more common for women age 40-49.1 Aside from false
positives there is overdiagnosis. Overdiagnosis occurs when an early stage invasive breast cancer
is found in a woman that will likely die from another cause before succumbing to the breast
cancer, most commonly seen in older women. In younger women it is when the detected DCIS
breast cancer will never progress to an invasive cancer.1 Ultimately, the number of women that
would need to be screened to prevent one death from breast cancer is 1904 among women age
39-49. The number of women that would need to be screened to prevent one death from breast
cancer is 1339 among women age 50-59. The number of women that would need to be screened
to prevent one death from breast cancer is 377 among women age 60-69.1
Screening Controversy
Of all the behaviors impacting the development of late-stage breast cancer diagnosis, the
most influential behavioral factor on late-stage diagnoses is mammography screening.10,29 In
order to prevent the disease’s progression to the third or fourth stage, the disease would have to
be found and treated earlier. To accomplish this, breast cancer needs to be detected before it can
be felt by the woman or clinicians.9 Not only is mammography screening the most effective
measure to prevent late-stage diagnosis among all women, it is the measure most effective
among African American women.30 The recommendations for breast cancer screenings
generated by organizations like the USPSTF, World Health Organization, ACOG, and ACS
directly impact the likelihood and frequency of a woman in this population getting

14

mammography screenings. Unfortunately, leading professional organizations do not all agree on
the best mammography screening guidelines.
Studies of the USPSTF’s 2009 recommendations for mammography screening for the
general population with normal risk of developing breast cancer has been varied but show little
association mortality reduction though it has been studied through various data sources.32 Amy
Wang et al. conducted a retrospective, interrupted time-series analysis using insurance claims to
determine the impact of the 2009 recommendation change from annual to biennial screenings on
insured women’s mammography screening practices. They found that there was a small drop in
the 40-49 age group but no impact on the 50-64 age group.69 Qin et al. also looked at medical
insurance claims and found mammography screening rates among US women age 40-49
decreased following the 2009 recommendation change from USPSTF.70 A decrease was also
found in mammography screening rates among Medicare Part B patients following the screening
recommendations.71
Looking at patient records for a large non-profit Oregon Health system, Nelson et al.
found that mammography screening among women aged 50-74 increased, while decreasing for
patients under the age of 50 and over the age of 74 in accordance with the new screening
recommendations. The population in this study was mostly insured with only 3.2% without
commercial or public insurance and only 2.3% covered by Medicaid.72 Sprague et al. studied the
impact of the USPSTF recommendations on mammography screening among Vermont women
using a statewide registry. They noted a decrease in mammography screening after the 2009
recommendations were released.73 Chang et al. found little change in mammography use in
surveyed Medicare recipients before and after the recommendation change except for African
American women in which they found no change at all.74 Lee et al. studied mammography use
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among African American and white community members in Arkansas. They found that there
was a decline in mammography use for white women but no significant change in
mammography use among African American women except for older women with no postsecondary education.75
Looking at data from the Breast Cancer Surveillance Consortium, Wernli et al. found that
the screening interval between mammography screenings did not increase following the USPSTF
guideline changes. It is important to note that their study population in the post period was more
likely to have a college education, be in the highest quartile income level and live in an urban
environment.76 Using National Health Interviews Surveys, Fedewa et al. found that
mammography screenings only decreased for higher socioeconomic younger women.77 Block et
al. looked at the mammography use specifically among women age 40-49 in the year following
the recommendation changes and found no change using BRFSS data.78 Gray and Picone also
found that USPSTF recommendations lead to a reductions in mammography screening rates
across all age groups using the BRFSS.79 However, Dehkordy et al. found a decrease in
mammography screening rates among all age groups with similar trends among insured women
using data from the BRFSS.80
The impact of the change of the recommendations on actual mammography screening
practices has been examined multiple times, but the actual impact of the change on breast cancer
stage at diagnosis has been examined at an Atlanta hospital and through national registries.
Simulating cancer stage distributions from patient records for the tumor registry of a large safety
net hospital in Atlanta, GA, Habtes et al. found that the USPSTF recommendations lead to later
breast cancer stages than the ACS.81 They broaden the reach of the study and still found the ACS
guidelines produce a higher proportion of stage I breast cancers and decreased the proportion of
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stage II and III breast cancers compared to USPSTF guidelines. The ACS guidelines also offered
higher 5-year survival estimates than the USPSTF guidelines. They also found that the ACS
guidelines would produce a greater savings ($5,528) than the USPSTF guidelines. They felt their
findings supported the use of ACS guidelines among low-income African American women
treated in public urban hospitals.82 In contrast to the study completed by Farley et al.,
O’Donoghue et al. found that the USPSTF guidelines resulted in substantial savings over current
practices and annual screenings for 85% of the population. Specifically, a savings of $5.4 billion
and $7.7 billion annually could be seen compared to current mammography screening practices
and annual mammography screenings, respectively.83 Instead of looking at a single hospital, Guo
et al. looked at national cancer registries and found that the change in mammography screening
guidelines from USPSTF slightly increased in situ, localized, and distant breast cancers, but
decreased the incidence of regional cancer.84 The literature has covered insured women at length,
but analysis of the effect of the recommendation change on the uninsured is lacking. The
question then becomes what impact does the change in recommendations have on African
American women that are already more likely to have a late-stage diagnosis?
Family History
All of the mammography screening recommendations are contingent on a woman having
average risk of developing breast cancer. An integral component of determining that risk is
family history of breast cancer. Family history is associated with an increased risk of more than
60% for developing breast cancer and the percentage of people with a first-degree family
member with a history of breast cancer has increased from 11% to 16% since the 1980s.85
Audrain-McGovern et al. found that as much as a third of women were not aware of the
added risk a family history of breast cancer poses and women with family history of breast
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cancer overestimate their risk.86 Knowing the importance of familial health history is only useful
if it is acted upon and 96% of people studied believed that knowledge of their family history was
important to their health but only 40% were actively collecting the information.87,88
Though having awareness of their family health history my increase risk reducing
behaviors in African Americans the majority of African American families have been found to
not discuss health conditions.89 Family members did not feel obliged to offer health information
and wanted to have control over which family members received the information. In other
instances, the lack of traditional familial relationships prevent family members from know the
health history of even first-degree relatives.90
Public Health Significance
Guide Leadership Decision Making
The decision makers for non-profits, insurance companies and funding agencies base
their activities on the recommendations of trusted health organizations. They put their faith in the
health organizations to provide the best recommendations based on the most accurate
information available. These non-profits and funding agencies are the ones directly impacting
whether some women get screened or not. For example, a funding agency that is following the
USPSTF recommendations will set the requirement that organizations using their funds can only
provide screenings to women that have not had a mammogram in the past 24 months. Initially, it
will appear as though they are able to assist twice as many women by screening biennially.
However, if a subset of their population suffers because the recommendations have not taken
into consideration their unique circumstances, they may be causing unknown harm.
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Preventing Health Disparities
The disparity in rates of late-stage breast cancer between African American and
Caucasian women has been well documented.2,20-22,26,59 We know African American women
have a lower lifetime incidence rate but have a higher mortality rate. We also know the gap
between the incidence rate is closing so as the incidence rate for Caucasian women plateaus the
rate for African American women is increasing.2 This could be due to the increased efforts to get
more African American women to complete regular mammography screenings. Regardless,
holding off mammography screenings for two years could potentially cause a widening of the
disparity because of the type of breast cancers with which African American women often
present. African American women present with breast cancers that are fast growing and resistant
to treatment. That coupled with the fact that African American women have a higher incidence
of breast cancer for ages 44 and younger could mean women likely to have an aggressive,
difficult to treat cancer would have to wait longer to be screened.11 The possibility of catching
their breast cancer in an early stage is drastically reduced if not eliminated entirely. The
reduction in opportunities for early cancer detection causes the number of late-stage cancer
diagnoses and/or the mortality rate to increase.
Specific Aims and Research Questions
Aims
Aim 1: Determine the impact of mammography screening frequency on breast cancer
diagnosis in African American women age 35 and older.
Aim 2: Determine if African American women age 35 and older typically have
knowledge of their family history of breast cancer.
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Research Questions
1. Does changing the time interval between mammography screenings affect the likelihood
of African American women being diagnosed with breast cancer?
2. Do African American women typically present with knowledge of their family history of
breast cancer?
METHODS
Data Source(s)
A publicly available data set of patient level data was retrieved from the Beast Cancer
Surveillance Consortium (BCSC) - https://www.bcsc-research.org/. The BCSC is a network of
eight breast imaging registries comprised of racially/ethnically and geographically diverse
populations. Registries included are The Kaiser Permanente WA Registry, Colorado
Mammography Advocacy Project, Metro Chicago Breast Cancer Registry, Vermont Breast
Cancer Surveillance System, New Hampshire Mammography Network, Carolina Mammography
Registry, New Mexico Mammography Project, and San Francisco Mammography Registry. The
data set includes the data from 2,392,998 screening mammograms. The women included in the
data set did not have a history of breast cancer and had received previous mammography
screenings in the five years prior to the index mammography screening, but not nine months
before the screening. Breast cancer diagnoses and pathology data were linked to the registry data
within a year of the mammography screening using SEER programs and tumor registries. Risk
factors (age, family history, race/ethnicity, height, weight, and health history) were self-reported
at the time of the indexed mammography screening.
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Study Variables
This study focused on the development of breast cancer during the time interval between
screenings. The time interval between screenings was defined as the time from the date of
diagnosis to the most recent prior mammography screening. Age at diagnosis is reported in five
year increments for ages 35-84. The breast cancer diagnosis variable is a dichotomous variable:
invasive or in situ breast cancer and no invasive or in situ breast cancer. Family history is
recorded as a categorical variable for zero, one, and two or more for the number of first-degree
relatives with a history of breast cancer. For the purposes of this study, the variable was
converted into a dichotomous variable for the presence or absence of knowledge of family
history.
Study Subjects
Inclusion criteria was being a non-Hispanic white or black woman age 35 years or older
at the time of breast cancer diagnosis from one of the mammography service providers
participating in the study. Exclusion criteria was being under the age of 35, missing diagnosis
information such as the date and stage of diagnosis, missing previous mammography history
(except for women 40 years old and younger), and identifying as any race/ethnicity other than
African American/black/non-Hispanic black or non-Hispanic white. The aim was to have a
sample size of 1025 African American/black/non-Hispanic black women and non-Hispanic white
women for a total of 2050 women.
Sample Size Calculation
𝑧 2 𝑝𝑞
=𝑛
𝑑2
1.962 ∙ 0.1214 ∙ 0.8786
= 1024.38 = 𝑛
0.022
21

Data Collection
The de-identified data was collected via electronic download. No personal health
information was retrieved. Data was stored on a firewall-protected server within the UTHealth
School of Public Health. At no time was the data be downloaded to portable devices such as a
USB drive. Data was de-identified before given to the researcher.
Data Analysis
STATA was used to run descriptive statistics and regression analyses. Summary statistics
and plots was used to study the data and any trends or outliers that may exist. For Aim 1, a
multivariate analysis of age, family history, previous mammogram result, breast density, and
hormone therapy use was conducted using Chi-square and z-tests for proportions to assess the
significance of any differences in the proportion of women diagnosed with breast cancer will be
conducted. For Aim 2, a multivariate analysis of age, previous mammogram result, breast
density, and breast cancer diagnosis will be conducted using Chi-square and z-tests for
proportions to assess the significance of any differences in the proportion of women diagnosed
with breast cancer was conducted.
Human Subjects Considerations
The study utilized retrospective patient level data. The protocol was submitted to IRB for
approval and received exempt status (HSC-SPH-19-1023).
Results Dissemination
Results will be presented to participating organizations to inform their clinical practices.
Results will also be written up for publication. The completed manuscript could be submitted to
one of the following peer reviewed journals American Journal of Preventive Medicine, Annals of
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Internal Medicine, American Journal of Public Health, Cancer, Journal of General Internal
Medicine, Women’s Health Issues, or The Breast Journal.
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JOURNAL ARTICLE 1
The Impact of Mammography Screening Frequency on Breast Cancer Diagnosis in African
American Women
American Journal of Preventive Medicine

Introduction
Breast cancer is the second most common cause of cancer-related death in women in the
United States, with one in eight women expected to develop the disease in their lifetime.1 There
will be an estimated 268,600 new cases of breast cancer and 41,760 deaths in 2019.2 Among
African American women, there are an expected 33,840 new cases diagnosed and 6,540 deaths
will have occurred in 2019.1 The incidence of breast cancer is increasing for both non-Hispanic
whites and non-Hispanic blacks, while mortality rates have remained stable for non-Hispanic
white women.1 Further, black and white women both have higher incidence and death rates for
breast cancer than other races/ethnicities.3 African American women are more likely to be
diagnosed with a late-stage breast cancer due to a myriad of reasons, such as lack of preventive
care, higher prevalence of aggressive cancers, and access to care.4-24 Breast cancer can be
detected through physical examination of the breast25 but is most commonly detected through
mammography screenings. Other screening methodologies exist, such as ultrasound, digital
breast tomosynthesis, and magnetic resonance imaging; however, mammography screenings are
directly linked to reducing breast cancer mortality. Mammography discovers the cancer before
signs and symptoms present and thus, remains the most effective method of reducing late-stage
diagnoses in African American women.7,26,27
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Discovering the presence of the disease while it is categorized as Stage I or II yields a
99% and 93% 5-year survival rate, respectively. Stage III has a 72% 5-year survival rate and
Stage IV has only a 22% 5-year survival rate.28 For women aged 40-60 years, mammography
screenings have been shown to reduce mortality from breast cancer by 15-32%.6,29,30 At every
stage of diagnosis, African American women have a lower 5-year survival rate than white
women. White women have a 98% and 97% 5-year survival rate for stages I and II. They have
76% 5-year survival rate for stage III and 27% for stage IV. African American women have
97%, 88%, 64%, and 19% 5-year survival rates for stages I-IV, respectively. African American
women specifically have a 40% increased risk of dying from breast cancer than their Caucasian
counterparts, though they now have similar incidence rates.1 Though numerous factors play into
their mortality disparity such as personal behavioral risk factors, socioeconomic status, and
access to care, African American women also present with more aggressive breast cancers that
are more difficult to treat and grow more rapidly.31-35
Mammography screenings have been found to be the most cost effective method of
diagnosing breast cancer.36 Organizations such as the U.S. Preventive Services Task Force
(USPSTF) have made recommendations that women of a certain age get mammography
screenings in an effort to reduce, if not prevent, breast cancer mortality. The recommendations
for breast cancer screenings generated by organizations such as USPSTF, World Health
Organization, American Congress of Obstetricians and Gynecologists, and American Cancer
Society directly impact the likelihood that and frequency with which a woman gets
mammography screenings. Prior to November 2009 the USPSTF recommendation was that
women complete annual mammography screenings starting at age 40.37,38 In November 2009,
and later reinforced in January 2016, USPSTF changed the recommendation to biennial

25

mammography screenings for women aged 50-74. The USPSTF was unable to conduct
individual analyses of the impact of the screening interval on different racial and ethnic groups.
In fact, the USPSTF stated that there was not enough evidence to fully support the biennial
screening recommendation.39 Several studies have looked at the change in general screening
practices post recommendation change, but the results have been mixed. A few studies have
noted that they saw no change in the African American population but that could be due to the
same issues and barriers that prevent these women from adhering to mammography screenings in
the first place.40,41 Lee et al, compared the mammography usage of African American and white
women in Arkansas before (2007–2010) and after (2011–2013) the mammography
recommendation change. They found no change in mammography screening practices for
African American women aged 40-74. Chang et al studied the change in mammography
screening practices in the 3-year period before and after the mammography screening guideline
recommendation change in women with Medicare and found that the African American women
were the only group not to decrease their mammography usage. In modeling the outcomes of
African American women adhering to the USPSTF’s recommendations, Habtes et al. found that
the recommendations lead to an increase in late stage diagnoses as opposed to the American
Cancer Society’s recommendations.42 Therefore, this study will evaluate the proportion of
African American women that were diagnosed with breast cancer within one year of a previous
mammography screening prior to the implementation of the mammography screening guideline
changes from USPSTF to explore the potential for the guideline change to have impacted this
specific high-risk population.
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Methods
Data Source
Data came from a de-identified, patient-level public dataset from the Breast Cancer
Surveillance Consortium (BCSC) - https://www.bcsc-research.org/.43-47 The BCSC is a network
of eight breast imaging registries comprising racially/ethnically and geographically diverse
populations. Seven mammography registries, Carolina Mammography Registry, Colorado
Mammography Project, Group Health Cooperative's Breast Cancer Surveillance Project, New
Hampshire Mammography Network, New Mexico Mammography Project, San Francisco
Mammography Registry, and the Vermont Breast Cancer Surveillance System, contributed data
that has been used in over 700 studies.43 The data set includes the data from 2,392,998 screening
mammograms collected between January 1, 1996-December 31, 2002. The women included in
the dataset did not have a history of breast cancer and had received previous mammography
screenings in the five years prior to, but not in the nine months before, the index mammography
screening. Breast cancer diagnoses and pathology data were linked to the registry data within a
year of the mammography screening using SEER programs and tumor registries. Risk factors
(age, family history, race/ethnicity, height, weight, and health history) were self-reported via
questionnaire at the time of the indexed mammography screening. Lastly, breast density was
determined by a radiologist based on the mammography films included in the registry.
Study Participants
The study sample was limited to women identified as white or African American aged 35
years or older at the time of breast cancer diagnosis from one of the mammography service
providers participating in the study. African American women have been found to present with
early onset breast cancers more frequently than other racial groups.31-35 For this reason, women
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aged 35-39 have been included in this study even though most mammography screening
guidelines do not recommend women begin screening until age 40. The initial sample consisted
of a total of 766,119 women. The University of Texas Health Science Center’s Committee for
the Protection of Human Subjects reviewed the protocol for this study and deemed the study
exempt.
Variables
The independent variable of this study was the race of the women undergoing screening
and include white and black women. The dataset also includes a variable for ethnicity to denote
whether a woman identified as Hispanic white or Hispanic black, but since an equal percentage
of participates had an unknown ethnicity (7.22%) as identified as Hispanic (7.44%) the author
deemed this variable unreliable. To address the issue of the accuracy and consistency of ethnicity
reporting, all participants that identified as Hispanic were dropped from the data set (n= 55,304).
This decision was made based on the assumption that individuals were more likely to answer yes
when they are sure of their Hispanic heritage and unknown and/or no when there were no
Hispanic ties.
The dependent variable of this study was the diagnosis of breast cancer after receiving a
mammography screening within a year of their previous mammography screening. Breast cancer
diagnosis data was collected as a dichotomous variable (Diagnosis/No diagnosis).
Covariates in this study were age, breast density, number of first degree relatives diagnosed with
breast cancer, previous mammogram result, and use of hormone therapy.47-52 Age was collected
as an ordinal variable with 10 five-year age categories ranging from 35-84. The breast density
variable was an ordinal variable based on the Breast Imaging Reporting and Data System (BIRADS) coding system’s four breast density codes (Almost entirely fat, scattered fibroglandar
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densities, heterogeneously dense, and extremely dense). BI-RADS classifications describe the
degree of attenuation of mammography screenings due to the composition of breast tissue. As
breast tissue density increases, the sensitivity of mammography screenings decreases. The
sensitivity is highest for breasts that are categorized as almost entirely fat and lowest for breasts
that are categorized as extremely dense.53 The variable denoting the number of first-degree
relatives diagnosed with breast cancer is an ordinal variable ranging from zero to two or more.
The result of the participant’s previous mammogram was collected as a dichotomous variable to
denote whether or not the participant received a false positive from her previous mammography
screening. The use of hormone therapy was collected as a categorical variable based on the
woman’s use of hormone therapy (Yes, No, and Unknown).
Statistical Analysis
Descriptive statistics were run to get unadjusted proportions (%) on dependent and
independent variables as well as the covariates in the model. Chi-square tests were run to
evaluate the differences between breast cancer diagnosis for all variables and between races. Ztests for proportions was used to assess the significance of any differences in the proportion of
women diagnosed with breast cancer. To examine the association between breast cancer
diagnosis and race, logistic regression analyses were conducted. The multivariate analysis
controlled for age, breast density, the number of first degree relatives that have been diagnosed
with breast cancer, the result of the participant’s previous mammogram, and the use of hormone
therapy.
Sensitivity Analysis: For the sensitivity analysis, the regression analysis was conducted
looking at any possible associations among women below the age of 50. The sample was limited
to women that were aged 35-49 at the time of their mammography screening. The results of the
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crude and adjusted odds ratios were then compared to the initial results of the multivariate
analysis.
STATA, Version 16 was used to conduct the analyses.
Results
We found that the data set, as expected, had considerably more participants that identified
as white than as African American. The majority of the sample fell between the ages of 40-59
(62.6%), had scattered fibroglanduar densities (33.38 %) or heterogeneously dense breast
(29.90%), if known, had no first degree relatives with a previous breast cancer diagnosis
(72.38%) and had unknown hormone therapy usage (43.65%). Table 2.1 shows the breakdown of
study variables stratified by race.
The proportions of women in each age group were significantly different for white and
African American women both overall and at every age group. Although the majority of the
study population fell between the ages of 40 and 59, 62.5% of white and 65.1% of African
American women fell in these age groups. There was a significantly higher proportion of African
American women in the 35-39 (p=0.0000), 40-44 (p=0.0000), and 45-49 (p=0.0000) age groups
when compared to the proportion of white women in the same age groups.
For African American women specifically, the 35-39 (p=0.002), 40-44 (p=0.006), 45-49
(p=0.005), 75-79 (p=0.029), and 80-84 (p=0.037) age groups were statistically different from the
African American study population. The 40-44 and 45-49 age groups had a significantly higher
proportion of women in them when compared to the overall group. The 35-39, 75-79, and 80-84
had a significantly lower proportion of women in them when compared to the overall group.
The 35-39, 40-44, 45-49, 50-54 age groups had a lower proportion of women diagnosed with
breast cancer. Whereas the 55-59, 60-64, 65-69, 70-74, 75-79, and 80-84 age groups all
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experienced an elevated proportion of women diagnosed with breast cancer. Women under the
age of 50 were also significantly less likely to have developed breast cancer within a year of their
previous mammography screening.
The sample saw an elevated odds ratio for women with breasts composed almost entirely
of fat (1.20, CI 1.16-1.24) more so than for women with scattered fibroglandular densities and
heterogeneously dense breasts (1.16, CI 1.14-1.18). The African American women in the study
had a lower odds ratio for having extremely dense breasts (0.81, CI 0.78-0.84).
The probability of receiving a cancer diagnosis within a year of having received a
mammography screening for each race was analyzed via logistic regression. Table 2.2 shows the
crude and adjusted odds ratios from the logistic regression analyses. A significant association
was not found between race and the likelihood of being diagnosed with either invasive or noninvasive breast cancer. The covariates, however, were all significant apart from the number of
first-degree relatives diagnosed with breast cancer.
Discussion
Our findings show that African American women are not at an increased risk of
developing breast cancer within the year between mammography screenings compared to their
Caucasian counterparts. Interestingly, we showed a reduced risk of developing breast cancer
within a year in women with dense breast tissue. This result is contradictory to the existing
literature that has found women with higher density breast more likely to develop breast
cancer.54,55
This study differs from others studying this topic in that we included women aged 35-39
in our analysis.40,41,56-58 Although none of the previous or current recommendations include
women in the 35-39 age group, the more aggressive breast cancers African American women
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tend to present start developing at a younger age.31-35,59-63 To analyze the potential threat of being
diagnosed with a breast cancer within a year, this younger age group needed to be included as
well.
Habtes et al. found that the USPSTF’s recommendations lead to an increased number of
late stage breast cancer diagnoses among African American women compared to having women
follow the American Cancer Society’s mammography screening recommendations.42 The
difference in our findings could be that Habtes et al. compared the change in the number of
diagnoses within a single population whereas we are comparing the difference in diagnoses
between two populations.
We did see a greater proportion of African American women under the age of 50 being
diagnosed with breast cancer. Attention must be paid to this group of women. Additional
research is needed to see when breast cancer is developing to determine if following the
USPSTF’s guidelines would have a potential negative impact on this group of women and if so,
what can be done to challenge this problem. Additional research should look for commonalities
among this population to identify the potential for interventions, such as genetic testing, a more
detailed risk assessment, or a different time interval for screening.
Our unique contribution to the research is exploration of the impact of screening time on
a racial subgroup of women. The USPSTF stated they were not able to identify the
recommendation needs of each racial group individually. Since the African American population
already has an increased risk of breast cancer mortality, it is important to explore all
opportunities to exacerbate this risk.
From our research it appears healthcare leadership and funding agencies can continue to
follow the USPSTF’s recommendations. However, these findings do not guarantee an absence in
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increase in later stage breast cancer diagnoses. In the small percentage of women in our study
population that did develop breast cancer within a year, there is still the potential for the breast
cancer to progress should mammography screening be delayed for another year.
Strengths and Limitations
A strength of our study is that we used BCSC data. The USPSTF also utilized data from
the BCSC to conduct their analysis before changing the mammography screening
recommendations making our populations comparable. A limitation of this dataset is that it
lacked staging information and exact mammography screening dates to tell if there was a
common screening interval within which women were presenting with breast cancer or the stage
at which most women at a particular screening interval were diagnosed. It also lacks a good
representation of registries in the portion of the country with higher densities of African
American residents. Thus the dataset lacks a representative sample of African American women
overall. White women made up ~60% of the sample, which is close to the national percentage of
white women, but African American women only made up ~5%, which is substantially below
the 13% national percentage of African American women.
The study used the development of breast cancer within a year of a previous
mammography screening and before the age of 50 as a proxy for determining if African
American women would be at risk for developing a more advanced breast cancer if following the
USPSTF’s recommendations. Our study was only able to look at the development of breast
cancer within a year of a previous mammography screening. As a result, we suggest more
research be done looking at the number of African American women diagnosed with breast
cancer within two years of their previous mammography screening to determine the effects of
delaying mammography screenings for two years.
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Conclusion
These findings suggest that though they are more likely to be diagnosed at a younger age,
African American women are not more likely to be diagnosed with breast cancer within a year of
a previous mammography screening. Thus, the recommendation that women receive
mammography screenings every two years appears to be appropriate for the majority of women.
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Table 1.1: Study Demographics
N
656,489
Age
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
Young
No
Yes
Density
Almost entirely
fat
Scattered
fibroglandular
densities
Heterogeneously
dense
Extremely dense
Unknown
Number of Relatives
Zero
One
Two or more
Unknown
Family History
Known
Unknown
Previous Mammogram
Negative
False Positive
Unknown
Hormone Use
No
Yes
Unknown
Invasive Breast Cancer
No
Yes
Breast Cancer
No
Yes

White
percentage
92.4%

N
54,326

Black
percentage
7.6%

p-value
<0.0001

17,870
100,561
112,448
113,495
83,093
63,369
55,879
49,843
37,890
22,041

2.7%
15.3%
17.1%
17.3%
12.7%
9.7%
8.5%
7.6%
5.8%
3.4%

1,914
9,315
10,442
9,199
6,406
5,033
4,454
3,642
2,542
1,379

3.5%
17.1%
19.2%
16.9%
11.8%
9.3%
8.2%
6.7%
4.7%
2.5%

425,610
230,879

64.8%
35.2%

32,655
21,671

60.1%
39.9%

<0.0001

<0.0001
38,653

5.9%

3,801

7.0%

217,437

33.1%

19,837

36.5%

194,673

29.7%

17,862

32.9%

40,800
164,926

6.2%
25.1%

2,773
10,053

5.1%
18.5%

476,857
81,448
3,999
94,185

72.6%
12.4%
0.6%
14.3%

37,661
5,019
154
11,492

69.3%
9.2%
0.3%
21.2%

562,304
94,185

85.7%
14.3%

42,834
11,492

78.8%
21.2%

438,547
9,207
208,735

66.8%
1.4%
31.8%

34,509
840
18,977

63.5%
1.5%
34.9%

189,699
180,356
286,434

28.9%
27.5%
43.6%

21,748
8,749
23,829

40.0%
16.1%
43.9%

652,360
4,129

99.4%
0.6%

54,016
310

99.4%
0.6%

651,430
5,059

99.2%
0.8%

53,937
389

99.3%
0.7%

<0.0001

<0.0001

<0.0001

<0.0001

0.097

0.161
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Table 1.2: Crude Regression Models for Demographics
OR

CI 95%

p-value

35-39

1.30

1.24-1.37

<0.0001

40-44

1.14

1.12-1.17

<0.0001

45-49

1.15

1.13-1.18

<0.0001

50-54

0.98

0.95-1.00

0.035

55-59

0.92

0.90-0.95

<0.0001

60-64

0.96

0.93-0.99

0.003

65-69

0.96

0.93-0.99

0.012

70-74

0.87

0.84-0.91

<0.0001

75-79

0.8

0.77-0.84

<0.0001

80-84

0.75

0.71-0.79

<0.0001

1.22

1.20-1.25

<0.0001

Almost entirely
fat
Scattered
fibroglandular
densities
Heterogeneously
dense
Extremely dense

1.20

1.16-1.24

<0.0001

1.16

1.14-1.18

<0.0001

1.16

1.14-1.18

<0.0001

0.81

0.78-0.84

<0.0001

Unknown

0.68

0.66-0.69

<0.0001

0.62

0.61-0.64

<0.0001

1.16

1.13-1.18

<0.0001

0.61

0.60-0.62

<0.0001

Age

Young
Density

Family History
Previous
Mammogram
Hormone Use
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Table 2.1: Crude and Adjust Logistic Regression Models for Cancer
Crude
OR

Adjusted

CI 95%

p-value

Age
35-39

0.36

0.27-0.47

<0.0001

40-44

0.40

0.36-0.44

<0.0001

45-49

0.62

0.57-0.67

<0.0001

50-54

0.84

0.78-0.91

<0.0001

55-59

1.21

1.12-1.31

<0.0001

60-64

1.37

1.26-1.48

<0.0001

65-69

1.56

1.44-1.69

<0.0001

70-74

1.59

1.46-1.73

<0.0001

75-79

1.68

1.53-1.85

<0.0001

80-84

1.57

1.38-1.77

<0.0001

0.43

0.40-0.46

<0.0001

Young
Density

OR

CI 95%

p-value

1.16

1.15-1.18

<0.0001

0.46

0.42-0.50

<0.0001

1.06

1.05-1.07

<0.0001

Almost entirely
fat
Scattered
fibroglandular
densities
Heterogeneously
dense
Extremely dense

0.41

0.34-0.48

<0.0001

0.82

0.77-0.87

<0.0001

1.13

1.07-1.20

<0.0001

1.10

0.98-1.22

0.0886

Unknown

1.25

1.18-1.33

<0.0001

0.96

0.89-1.03

0.2837

1.17

1.11-1.24

<0.0001

1.02

1.02-1.03

<0.0001

0.79

0.74-0.83

<0.0001

0.99

0.98-0.99

<0.0001

1.00

0.99-1.01

0.662

0.98

0.88-1.09

0.728

Family History
Previous
Mammogram
Hormone Use
Number of
Relatives
Race

0.93

0.84-1.03

0.1611
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Table 2.2: Crude and Adjust Logistic Regression Models for Invasive Cancer
Crude
OR

Adjusted

CI 95%

p-value

Age
35-39

0.34

0.25-0.46

<0.0001

40-44

0.37

0.33-0.42

<0.0001

45-49

0.59

0.53-0.65

<0.0001

50-54

0.81

0.75-0.88

<0.0001

55-59

1.24

1.14-1.35

<0.0001

60-64

1.37

1.25-1.50

<0.0001

65-69

1.55

1.42-1.70

<0.0001

70-74

1.69

1.54-1.85

<0.0001

75-79

1.75

1.58-1.94

<0.0001

80-84

1.66

1.45-1.90

<0.0001

Density
Almost entirely
fat
Scattered
fibroglandular
densities
Heterogeneously
dense
Extremely dense

0.43

0.36-0.52

<0.0001

0.84

0.79-0.90

<0.0001

1.11

1.04-1.19

0.0009

1.04

0.92-1.17

0.5769

Unknown

1.27

1.19-1.35

<0.0001

Number of
Relatives
Family History

OR

CI 95%

p-value

1.17

1.16-1.19

<0.0001

1.06

1.05-1.07

<0.0001

1.00

1.00-1.01

0.331

0.94

0.87-1.02

0.1495

1.17

1.10-1.25

<0.0001

1.02

1.02-1.03

<0.0001

0.77

0.72-0.82

<0.001

0.98

0.97-0.99

<0.0001

Young

0.4

0.37-0.44

<0.0001

0.44

0.40-0.48

<0.0001

Race

0.91

0.81-1.02

0.0972

0.96

0.85-1.08

0.476

Previous
Mammogram
Hormone Use
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Introduction
Breast cancer is the second most common cause of cancer-related death in women in the
United States with one in eight women expected to develop the disease in their lifetime.1 As the
most commonly diagnosed cancer in African American women, it accounts for a third of all
cancer diagnoses. Black women have a 40% increased risk of dying from breast cancer than their
White counterparts.1 Several factors contribute to the mortality disparity that exists between
Black and White women including, but not limited to, access to care.2-6 Mammography
screenings are known to reduce breast cancer mortality by 15-32% so receiving timely
mammography screenings is critical for all women and especially African American women.7-9
The appropriate time to engage in screening is an area of much debate. Several recommendations
exist for when a woman should receive a mammogram. The American Cancer Society suggests
that women of average risk undergo annual mammography screenings beginning at the age of 45
and continuing until age 54. Women age 55 and older should begin screening biennially or have
the opportunity to continue screening annually. Women age 40 through 44 should have the
opportunity to begin annual screening. Women should continue mammography screenings as
long as they are in good health and they have a life expectancy of at least 10 years.10,11 The
American College of Obstetrics and Gynecology recommends women of average risk should
begin mammography screenings at age 40.12 The U.S. Preventive Services Task Force (USPSTF)
recently affirmed their revision to mammography screening recommendations. Contrary to their
previous recommendations that women aged 40 and older receive annual mammography
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screenings, the USPSTF now recommends average risk women receive a mammography
screening biennially from ages 50-74.13
The common thread among the recommendations is that they are intended only for
women of average risk. Average risk is defined as a woman lacking a personal history of breast
cancer, a genetic mutation known to increase breast cancer risk, and/or a history of exposure to
chest radiation in childhood.12 Based on this, a woman’s knowledge of her family history of
breast cancer is critical. Family history is associated with an increased risk of more than 60% for
developing breast cancer.14 Also, the proportion of women with a first-degree family member
with a history of breast cancer has increased from 11% (1980s) to 16% (2010).14 Lack of
knowledge of family history and risk is a concern in women of screening age. AudrainMcGovern et al. found that as much as a third of women are unaware of the additional risk a
family history of breast cancer poses to their health.15 Studies found that although 96% of people
studied believed that knowledge of their family history was important to their overall health,
only 40% of people who believe it is important were actively collecting the information.16,17
Familial communication style also impacts knowledge of history and risk. Hovick et al.
conducted focus groups and interviews with African Americans in Houston, Texas to assess
family communication styles related to health issues. They found that few participants reported
having good communication. The majority were found not to discuss health issues with their
families for a variety of reasons. Individuals that did not want their information spread to
unknown people felt it necessary to forgo sharing it at all. Participants expressed feelings of sole
ownership of their health history and it was not anyone else’s business. Others did not want to
burden family members with their issues and thus kept the information regarding their health to
themselves. Frequently, there was an absence of knowledge sharing because the family members
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had no way of getting the information, either the family members with diseases did not go to the
doctor and did not know the information or family members were not in contact with their
relatives. The authors further stated that non-communication came up in every focus group and
every interview.18 Studies have found that African American women are less likely to discuss
family health issues and/or have genetic testing as compared to other groups,18,19 which leads to
our research question. We know that women with a family history of breast cancer are more
likely to get mammography screenings, but how many African American women attend their
mammography screening appointment knowing their family history of breast cancer?
Methods
This study used data from the Breast Cancer Surveillance Consortium (BCSC) https://www.bcscresearch.org/,14,20-23 a publicly available dataset of de-identified, patient-level data collected from
the BCSC’s seven breast imaging registries. Carolina Mammography Registry, Colorado
Mammography Project, Group Health Cooperative's Breast Cancer Surveillance Project, New
Hampshire Mammography Network, New Mexico Mammography Project, San Francisco
Mammography Registry, and the Vermont Breast Cancer Surveillance System contributed data.24
The dataset included data from 2,392,998 screening mammograms collected between January 1,
1996-December 31, 2002. The women included in the dataset did not have a history of breast
cancer. Breast cancer diagnoses and pathology data were linked to the registry data within a year
of the mammography screening using SEER programs and tumor registries. Risk factors (age,
family history, race/ethnicity, height, weight, and health history) were self-reported via
questionnaire at the time of the indexed mammography screening. Lastly, breast density was
determined by a radiologist based on the mammography films included in the registry.
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Study Participants
The study sample was limited to women identified as white or black aged 35 years or
older at the time of breast cancer diagnosis from one of the mammography service providers
participating in the study. We dropped participants that identified as Hispanic from this study.
African American women have been found to present with early onset breast cancers more
frequently than other racial groups.25-29 For this reason, women aged 35-39 have been included in
this study even though most mammography screening guidelines do not recommend women
begin screening until age 40. The sample consisted of a total of 766,119 women. The University
of Texas Health Science Center’s Committee for the Protection of Human Subjects reviewed the
protocol for this study and deemed the study exempt.
Variables
The independent variable of this study was the race of women receiving mammography
screenings, categorized as white and black women. The data sources only categorized women as
white and black, so the assumption was made that the black category includes women that
identify as African American. The dataset also includes a variable for ethnicity to denote whether
a woman identified as Hispanic white or Hispanic black, but since an equal percentage of
participates had an unknown ethnicity (7.22%) as identified as Hispanic (7.44%) the author
deemed this variable unreliable. To address the issue of the accuracy and consistency of ethnicity
reporting, all participants that identified as Hispanic were dropped from the dataset (n= 55,304)
leading to a sample size of (n=710,815) for this analysis. This decision was made based on the
assumption that individuals were more likely to answer yes when they are sure of their Hispanic
heritage and unknown and/or no when there were no Hispanic ties.
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The dependent variable of this study was the knowledge of breast cancer diagnoses
among first degree relatives. The number of first degree relatives that have been diagnosed with
breast cancer data was collected as an ordinal variable with responses for 0 relatives, 1 relative, 2
or more relatives, and unknown. The variable was then converted into a dichotomous variable,
knowledge of breast cancer diagnoses among relatives versus absence of knowledge of breast
cancer diagnoses among relatives.
Covariates in this study were age, breast density, the number of first degree relatives that
have been diagnosed with breast cancer, and the result of the participant’s previous
mammogram. Age was collected as an ordinal variable with 10 five-year age categories ranging
from 35-84. The breast density variable was an ordinal variable based on the Breast Imaging
Reporting and Data System (BI-RADS) coding system four breast density codes (Almost entirely
fat, scattered fibroglandar densities, heterogeneously dense, and extremely dense). BI-RADS
classifications describe the level of sensitivity of mammography screenings for each common
type of breast tissue composition. The sensitivity of mammography screenings decreases as
breast tissue density increases. The sensitivity is highest for breasts that are categorized as almost
entirely fat and lowest for breasts that are categorized as extremely dense.30 The result of the
participant’s previous mammogram was collected as a dichotomous variable to denote whether
or not the participant received a false positive from her previous mammography screening.
Statistical Analysis
Descriptive statistics were run to get unadjusted proportions (%) on the dependent
variable, the independent variable, and the covariates in the model. Chi-square tests were run to
evaluate the differences between women with a knowledge of family breast cancer diagnoses for
all variables and between races. Z-tests for proportions were used to assess the significance of
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any differences in the proportion of women diagnosed with and without knowledge of family
breast cancer diagnoses. To examine the association between knowledge of family breast cancer
diagnoses and race, logistic regression analyses were conducted. The multivariate analysis
controlled for age, breast density, and the result of the participant’s previous mammogram.
Sensitivity Analysis: For the sensitivity analysis, the regression analysis was conducted
looking at any possible associations among women with knowledge of family breast cancer
diagnoses by the number of relatives with breast cancer diagnoses. The analysis utilized the data
as collected, as an ordinal variable with responses for 0 relatives, 1 relative, 2 or more relatives,
and unknown. The results of the crude and adjusted odds ratios were then compared to the initial
results of the multivariate analysis.
STATA, Version 16 was used to conduct the analyses.
Results
The dataset had considerably more participants that identified as white (92.36%) than as
black (7.64%). The majority of the sample also fell between the ages of 40-59 (62.6%), had
scattered fibroglandular densities (33.38 %) or heterogeneously dense breast (29.90%), if known,
had no first degree relatives with a previous breast cancer diagnosis (72.38%) and had unknown
hormone therapy usage (43.65%). Table 3.1 shows the breakdown of study variables stratified by
race.
The proportions of women in each age group were significantly different for white and
black women both overall and at every age group. Although the majority of the study population
fell between the ages of 40 and 59, 62.5% of white and 65.1% of black women fell in these age
groups. There was a significantly higher proportion of African American women in the 35-39
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(p=0.0000), 40-44 (p=0.0000), and 45-49 (p=0.0000) age groups when compared to the
proportion of white women in the same age groups.
For African American women specifically, the 35-39 (p=0.002), 40-44 (p=0.006), 45-49
(p=0.005), 75-79 (p=0.029), and 80-84 (p=0.037) age groups were statistically different from the
African American study population. The 40-44 and 45-49 age groups had a significantly higher
proportion of women in them when compared to the overall group. The 35-39, 75-79, and 80-84
had a significantly lower proportion of women in them when compared to the overall group.
The 35-39 (p=0.0000), 40-44 (p=0.0000), 55-59 (p=0.0454), 60-64 (p=0.0000), 65-69
(p=0.0000), 70-74 (p=0.0000), and 80-84 (p=0.0048) age groups had a significantly higher
proportion of women without knowledge for their family history of breast cancer. Although ages
45-49 (p=0.1271), 50-54 (p=0.6457), 75-79 (p=0.0753) did not have a significantly higher
proportion of women without family history knowledge, women under the age of 50 as a whole
did have a significantly higher proportion of women without that knowledge (p=0.0000).
In our sample, 85.13% of women had knowledge of their family history of breast cancer
with 85.65% of the white women in the study having this knowledge compared to 78.85% of
African American women. African American women had a higher proportion of women without
knowledge for their family history of breast cancer. Looking specifically at the study participants
with familial knowledge, the breakdown of the number of known first degree relatives with a
breast cancer diagnosis was similar between white and African American women. We found
that 72.64% of white women reported having no first degree relatives with a previous breast
cancer diagnosis compared to 69.32% of African American women. Also, 12.41% of white
participants and 9.24% of African American participants reported having one first degree relative
with a previous breast cancer diagnosis. Very few women reported having two or more first
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degree relatives with a previous breast cancer diagnosis with only 0.61% for white women and
0.28% for African American women.
Women who had received a false-positive from a previous mammography screening also
were more likely to know their family history of breast cancer.
We used logistic regression to analyze the probability of a woman knowing her family
history of breast cancer at the time of her mammography screening. Table 3.2 shows the crude
and adjusted odds ratios from the logistic regression analyses. A significant association was
found between race and the likelihood of a woman knowing her family history of breast cancer at
the time of her mammography screening (p=0.0000). All of the covariates, with the exception of
actual cancer diagnosis, were significant (p=0.0000). African American women are significantly
less likely to know their family history of breast cancer. Women under the age of 50 were 10%
more likely to know their family history of breast cancer.
Discussion
These findings show that African American women do not typically present to their
mammography screening appointments with knowledge regarding family history of breast cancer
diagnoses. There was no association between the women that presented with family history
knowledge and those that developed breast cancer within a year of their previous mammography
screening. In agreement with Shiyanbola et al., we found an association between having first
degree relatives with a breast cancer diagnosis and the diagnosis of breast cancer among study
participants. Our study population had a lower percentage of women with at least one first degree
relative with a previous breast cancer diagnosis than the 16% Shiyanbola et al. reported at just
12.74%.14
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The significantly lower proportion of African American women with a knowledge of
relatives’ previous breast cancer diagnoses speaks to Hovick et al.’s findings that African
American families seldom discuss health histories. The literature offers conflicting views as to
where the issue lies regarding the transferal of family health information. Hovick et al. suggested
that older individuals choose not to share the information while Koehly et al. found older African
Americans more likely to gather the information.18,31 Hovick et al. and Forrest et al. also found
that younger individuals elect not to hear the information.18,32 Our results seem to be in line with
their findings as our participants aged 45-54 were found to have knowledge of familial breast
cancer diagnoses.
We did see a statistically significant higher proportion of women with knowledge of their
family history that had previously received a false positive mammography screening. This may
be due to women being more inclined to discuss their family history of breast cancer with their
relatives when they receive a false positive mammography screening.
In establishing clinical procedures for healthcare providers, leadership should consider
paying close attention to the manner in which health histories are gathered from their patients.
Perhaps patients could be counseled on exploring both breast cancer and overall health histories
with their families in prior to their mammography screening appointment by their primary care
physician. This conversation could alert healthcare providers to the lack of knowledge of some
of their patients and alter the manner in which they provide care.14-18,33 The knowledge of
familial histories would determine when clinicians would recommend women begin
mammography screenings.
This study’s strength is that we used BCSC data. The USPSTF utilized the BCSC’s data
to conduct their analysis before electing to change the recommendations for mammography
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screening making our analyses comparable. However, as with any research study, there are
limitations. The primary limitation in this study is the limited race/ethnic representation of
registries in parts of the country with higher densities of African Americans. Thus the dataset
lacks a representative sample of African American women. White women made up ~60% of the
sample but black women only made up ~5%. 60% is close to the national percentage of white
women, but 5% is nowhere near the 13% needed for black women.
Conclusion
The results from this study show that the previous breast cancer diagnoses of first degree
family members is not something African American women have knowledge of when they come
in for their mammography screening. However, though African American women do not
typically present with knowledge of familial breast health, they are coming in for mammography
screenings and the motivation for their action could be useful information in the fight to end the
breast cancer mortality disparity.
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Table 3.1: Crude and Adjust Logistic Regression Models for Knowledge of Family History
Crude
OR

CI 95%

P value

Age
35-39

1.24

1.19-1.29

<0.0001

40-44

1.11

1.09-1.13

<0.0001

45-49

1.02

1.00-1.04

0.0229

50-54

1.01

0.99-1.03

0.3191

55-59

0.98

0.96-1.00

0.1011

60-64

0.94

0.92-0.96

<0.0001

65-69

0.90

0.88-0.92

<0.0001

70-74

0.92

0.89-0.94

<0.0001

75-79

0.97

0.94-0.99

0.0162

80-84

1.03

0.99-1.07

0.1621

Density

Adjusted by Invasive Cancer

Adjusted by Breast Cancer
OR
CI 95%
P value

OR

CI 95%

P value

0.96

0.96-0.97

<0.0001

1.04

1.03-1.04

<0.0001

0.85

0.85-0.86

<0.0001

1.11

1.11-1.11

<0.0001

Almost entirely
fat
Scattered
fibroglandular
densities
Heterogeneously
dense
Extremely dense

1.46

1.42-1.51

<0.0001

1.52

1.50-1.55

<0.0001

1.50

1.47-1.52

<0.0001

1.73

1.68-1.79

<0.0001

Unknown

0.37

0.36-0.37

<0.0001

0.85

0.83-0.86

<0.0001

0.97

0.97-0.97

<0.0001

1.02

1.01-1.02

<0.0001

1.10

1.09-1.12

<0.0001

1.18

1.17-1.20

<0.0001

1.18

1.17-1.20

<0.0001

Race

0.62

0.61-0.64

<0.0001

0.57

0.55-0.58

<0.0001

1.24

1.22-1.27

<0.0001

Breast Cancer

0.96

0.89-1.03

0.2837

1.06

0.99-1.15

0.105

Invasive Cancer

0.94

0.87-1.02

0.1495

1.05

0.96-1.14

0.296

Previous
Mammogram
Young

63

Table 3.2: Crude and Adjust Logistic Regression Models for Number of Relatives with Breast Cancer
Crude
OR

CI 95%

P value

Age
35-39

1.64

1.59-1.68

<0.0001

40-44

0.85

0.84-0.86

<0.0001

45-49

0.92

0.91-0.93

<0.0001

50-54

0.92

0.91-0.93

<0.0001

55-59

0.98

0.96-0.99

0.0038

60-64

1.03

1.02-1.05

0.0002

65-69

1.10

10.8-1.12

<0.0001

70-74

1.14

1.12-1.16

<0.0001

75-79

1.16

1.14-1.19

<0.0001

80-84

1.14

1.11-1.18

<0.0001

Density

Adjusted by Invasive Cancer

Adjusted by Breast Cancer
OR
CI 95%
P value

OR

CI 95%

P value

1.04

1.03-1.04

<0.0001

1.04

1.03-1.04

<0.0001

1.11

1.11-1.11

<0.0001

1.11

1.11-1.11

<0.0001

Almost entirely
fat
Scattered
fibroglandular
densities
Heterogeneously
dense
Extremely dense

0.79

0.77-0.80

<0.0001

0.77

0.76-0.78

<0.0001

0.80

0.79-0.81

<0.0001

0.78

0.77-0.80

<0.0001

Unknown

1.93

1.91-1.96

<0.0001

1.07

1.06-1.09

<0.0001

1.02

1.01-1.02

<0.0001

1.02

1.01-1.02

<0.0001

0.92

0.91-0.93

<0.0001

0.89

0.88-0.90

<0.0001

0.89

0.88-0.90

<0.0001

Race

1.17

1.15-1.20

<0.0001

1.24

1.22-1.27

<0.0001

1.24

1.22-1.27

<0.0001

Breast Cancer

1.3

1.22-1.37

<0.0001

1.21

1.14-1.28

<0.0001

Invasive Cancer

1.3

1.22-1.39

<0.0001

1.21

1.14-1.28

<0.0001

Previous
Mammogram
Young

64

CONCLUSION
This dissertation was initiated with the goal of determining whether or not the U.S.
Preventive Services Task Force’s (USPSTF) recommendation for women aged 50-74 to receive
biennial mammography screening negatively impacts African American women, a group with
existing mortality disparities. The study does so by examining whether changing the time
interval between mammography screenings affects the likelihood of African American women
being diagnosed with breast cancer and if African American women typically present with
knowledge of their family history of breast cancer.
The analysis of breast cancer incidence showed that African American women are not at
an increased risk of developing breast cancer within the year between mammography screenings
when compared to their Caucasian counterparts. However, results showed a greater proportion of
African American women under the age of 50 being diagnosed with breast cancer. This is
concerning because this age group is completely omitted from mammography screening
practices when adhering to the most recent recommendations. Findings also showed that African
American women do not typically present to their mammography screening appointments with
knowledge regarding the past breast cancer diagnoses of their first degree relatives. Additional
research is needed to see when the breast cancer is developing to determine if following the
USPSTF’s guidelines would have the potential to negativity impact this group of women and
what can be done to challenge this problem. Research would need to look for commonalities
between impacted women to identify potential areas for interventions.
Given the current evidence, it appears healthcare leadership and funding agencies can
continue to follow the USPSTF’s recommendations with the caveat that the recommendations do
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not guarantee prevention of later stage breast cancer diagnoses in the women that develop breast
cancer between scheduled mammography screenings. In establishing clinical procedures for
health care providers, leadership should pay close attention to the manner in which health
histories are gathered from their patients. Clinicians should advise patients to discuss health
histories with their families in both the area of breast cancer and overall health.
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